Abstract

Background: Non-Hodgkin lymphoma is a common hematologic malignancy. This article aimed to estimate the trends of non-Hodgkin lymphoma (NHL) globally from 1990 to 2019.Methods: Data on the NHL burden were explored from the Global Burden of Disease study 2019. The trends of NHL burden were estimated using age-standardized rate (ASR) and estimated annual percentage change (EAPC).Results: The ASR of NHL incidence showed an increasing trend worldwide from 1990 to 2019, with an EAPC of.56 [95% CI: 0.45–0.66]. Meanwhile, increasing trends were observed in both sexes and in most geographic regions, particularly East Asia (EAPC = 3.57, 95% CI: 3.29–3.86). The most pronounced increasing trends were seen in Georgia (EAPC = 4.7, 95% CI: 4.20–5.21), followed by Belarus and Uzbekistan. However, death and disability-adjusted life years (DALYs) caused by NHL showed decreasing trends globally, in which the respective EAPCs were −0.09 (95% CI: −0.17 to −0.02) and −0.28 (95% CI: −0.35 to −0.22). Decreasing trends were mainly seen in high and high-middle sociodemographic index (SDI) areas. At the national level, the largest increasing trends of death and DALYs were observed in Georgia, in which the respective EAPCs were 4.54 (95% CI: 4.01–5.07) and 4.97 (95% CI: 4.42–5.52).Conclusions: Decreasing trends of death and DALYs caused by NHL were observed worldwide from 1990 to 2019, but NHL remains a substantial challenge globally. The findings would inform the strategies for reducing the burden of NHL.

Highlights

  • Non-Hodgkin lymphoma is a kind of lymphoma characterized by a wide range of morbid features and difficulties in diagnosis [1] and accounts for 90% of all lymphoma incidences [2].According to the Global Cancer Statistics 2018, the burden of non-Hodgkin lymphoma (NHL) aggravated in many regions, and reached 509,590 incidences and 248,724 deaths in 2018, Trends Analysis of Non-Hodgkin Lymphoma accounting for 2.8 and 2.6%, respectively, of the total incidence and mortality of 36 cancers involved [3]

  • The age-standardized incidence rate (ASIR) showed an increasing trend worldwide from 1990 to 2019 (EAPC = 0.56, 95% confidence interval (CI): 0.45– 0.66) (Table 1, Figure 1)

  • An increasing trend in ASIR was more pronounced in male patients (EAPC = 0.78, 95% CI: 0.69– 0.87) (Table 1)

Read more

Summary

Introduction

According to the Global Cancer Statistics 2018, the burden of non-Hodgkin lymphoma (NHL) aggravated in many regions, and reached 509,590 incidences and 248,724 deaths in 2018, Trends Analysis of Non-Hodgkin Lymphoma accounting for 2.8 and 2.6%, respectively, of the total incidence and mortality of 36 cancers involved [3]. In the 1970s, just over onefifth of people with NHL survived more than 10 years, but the proportion has increased to almost two-thirds [5]. In Western countries, the majority of NHL cases are B-cell lymphomas (∼85%), but T-cell lymphoma is less common (∼15%), while the reversed proportion occurs in developing regions [5, 11], which probably explains the significant geographic heterogeneity in the distribution of NHL burden. This article aimed to estimate the trends of non-Hodgkin lymphoma (NHL) globally from 1990 to 2019

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.